FDA Expands Keytruda® Approval for Front Line Treatment of NSCLC
On April 14, 2019, the FDA approved Keytruda® as first line monotherapy for non-small cell lung, NSCLC, cancer patients whose cancer cells express PD-L1 and have no genomic changes in…
On April 14, 2019, the FDA approved Keytruda® as first line monotherapy for non-small cell lung, NSCLC, cancer patients whose cancer cells express PD-L1 and have no genomic changes in…
Although we think of as one organ, it’s very different from left to right. The biology of what happens in the colon is very different from left to right and…